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Abstract
Multiple myeloma is the second most common hematological malignancy. It is a het-
erogeneous disease characterized by focal lesions of malignant plasma cells in the bone 
marrow. Since bone marrow biopsy is a single-site procedure, its potential is limited 
in discovering the many clones present in each patient. Thus, a new approach, liquid 
biopsy, seems to be more relevant in today’s world. Liquid biopsy can analyze circulating 
tumor cells or various circulating molecules (cell-free DNA, microRNA, long non-coding 
RNA and many others) that originated from the various tumor sites and thus will repre-
sent many different subclones. This review summarized current situation in research of 
liquid biopsies in multiple myeloma.
Keywords: multiple myeloma, liquid biopsy, non-coding RNA, circulating microRNA, 
cell-free DNA, circulating plasma cells
1. Introduction
Monoclonal gammopathies (MG) are a group of diseases characterized by proliferation of 
clonal plasma cells (PC). Physiological PC are terminally differentiated B cells, which secrete 
various types of antibodies used for neutralization of pathogens [1]. This essential function of 
PC is disrupted in MM patients, and abnormal cells overproduce monoclonal immunoglobu-
lin (M-Ig) [2]. Multiple myeloma (MM) and its precursor disease monoclonal gammopathy 
of undetermined significance (MGUS) are two most common MG. The less frequent MG 
include Waldenström macroglobulinemia, solitary plasmacytoma, light chains amyloidosis 
and plasma cell leukemia [3].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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MM is the second most common hematological malignancy [4]. It is caused by malignant 
transformation of PC, which infiltrate the bone marrow (BM) disrupting normal hematopoi-
esis. Moreover, they produce M-Ig that is found in serum and/or urine of MM patients. MM 
is characterized by a set of clinical features known as CRAB features (hypercalcemia, renal 
failure, anemia and bone lesions) [5, 6].
MM represents about 13% of all hematological and about 1% of all malignancies. The inci-
dence in the Czech Republic has been reported at 4.8/100000 per year [7], while in Europe it is 
slightly higher, 6/100000 per year [8]. Interestingly, MM is quite common in North America, 
Europe and Australia, while it is rare in the Middle East and Asia [9].
In 2003, the International Myeloma Working Group (IMWG) published diagnostic criteria for 
MM: infiltration of BM by malignant PC >10%, CRAB features and presence of M-Ig in serum 
and/or urine [2]. Thus, MM was treated only when CRAB feature(s) were fully developed. At 
that time, most treatment options were quite toxic, which is why treatment was postponed 
[10]. The past 10 years, however, have brought unprecedented new treatment options (immu-
nomodulatory drugs, proteasome inhibitors, monoclonal antibodies) that improved survival 
rates as well as quality of life of MM patients. This led to revision of diagnostic criteria in 2014 
from diagnostics based on clinical symptoms to diagnostics based on biomarkers allowing 
earlier treatment of the disease [6].
Since the new drugs have been introduced into clinics, detection of minimal residual dis-
ease (MRD) has become even more important as MRD negativity is a prognostic factor in 
MM. Moreover, sensitivity of the detection method is becoming an issue since new drugs 
induce deep response, and MRD needs to be measured with sensitivity up to 10−6. The two most 
common methods used for MRD detection are multiparametric flow cytometry and ASO-PCR 
(allele-specific PCR) [11–13]. ASO-PCR is based on the detection of patient-specific V(D)J rear-
rangement in bone marrow plasma cells (BMPC) [14]. Nowadays, next-generation sequencing 
(NGS) is gaining more attention as a more precise and modern method of detection. However, 
NGS needs to be standardized and more accessible before it can be used more broadly.
The genome of MM cells is highly unstable and harbors various cytogenetic abnormalities, 
including translocations, deletions or duplications. From the cytogenetic point of view, MM 
may be divided into two groups: hyperdiploid and non-hyperdiploid. Hyperdiploid genome 
is mostly characterized by trisomies of odd chromosomes (3,5,7,9,11,15,19,21) and is connected 
to better prognosis [5], while non-hyperdiploid genome is characterized by monosomies of 
chromosomes 8,13,14,16,17 and 22 and recurrent chromosomal translocations involving the 
immunoglobulin heavy chain (IgH) locus at 14q32. In MM, the most frequent chromosomal 
translocations are t(11;14)(q13;q32) (15–20% of MM patients) and t(4;14)(p16;q32) (12–15% of 
MM patients). Other translocations are less frequent, found only in less than 5% of patients 
(t(14;16)(q32; q23), t(14;20)(q32;q11) and t(6;14) (p21;q32)). In MM cells with t(11;14)(q13;q32), 
cyclin D1 gene is translocated under the control of immunoglobulin heavy chain enhancer. 
Similarly, cyclin D3 gene at 6p21 is overexpressed in MM cells carrying t(6;14)(p21;q32) [14].
In addition to MM being a genetically heterogeneous disease, it is also characterized by 
multifocal tumor deposits throughout the BM and focal lesions elsewhere. Malignant PC in 
these lesions carry various cytogenetic aberrations with varying level of prognostic value [15]. 
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Diagnosis and monitoring of MM are routinely performed using BM aspiration and/or BM 
biopsy [6]. However, discrepant results were described from analyses of different biopsy sites 
within the same patient [16, 17]. Diagnostic biopsies of the BM are obtained only from a single 
site in the BM what creates a sampling bias and provides only a limited molecular profile as 
all subpopulations of PC, so-called subclones, are not present in the BM [18].
Liquid biopsies represent one of the possible solutions for more comprehensive analysis of 
MM patients. Various targets, which can be analyzed in MM samples, include circulating 
tumor cells [19], cell-free DNA (cfDNA) [20], microRNA (miRNA) [21] and long non-coding 
RNA (lncRNA) molecules [22]. This review summarizes current knowledge of all aspects of 
liquid biopsies in MM.
2. Circulating plasma cells
In some cases, PC may migrate out of the BM into peripheral blood (PB), then they are called 
circulating PC (cPC) [23, 24]. While the reason for the migration is unclear, it is clear that these 
cPC lose (in some cases only temporarily) their dependence on the BM microenvironment due 
to the loss of adhesion molecules, increased proliferation, increased number of chromosomal 
aberrations and increased angiogenesis [25, 26]. The presence of cPC in newly diagnosed 
MM patients has been associated with shorter survival of patients, and it is an independent 
negative prognostic factor [24]. It is also possible that it is the first feature of extramedullary 
relapse, which is characterized by infiltration of PC into soft tissues and bad prognosis for 
patients [27]. In case that the number of cPC increases to over 20% in PB, it may turn into 
progression to secondary plasma cell leukemia [28].
cPC can be detected in a small fraction of newly diagnosed MM patients (15%) by conven-
tional morphology [29]. However, this frequency increases up to 50–70% once more sensitive 
techniques, such as flow cytometry, are used [30]. Interestingly, the presence of cPC has been 
associated with an increased risk of malignant transformation to symptomatic MM in MGUS 
patients as well as with an inferior survival among symptomatic newly diagnosed and relapse/
refractory MM [31]. In a study by Paiva et al., cPC were analyzed by multiparametric flow 
cytometry, FISH and cell cycle analysis; cPC were compared to paired PC samples from the 
BM. Their results showed that cPC are a unique subpopulation of malignant PC in MM; cPC 
are characterized by decreased expression of integrins (CD11a/CD11c/CD29/CD49d/CD49e) 
and adhesion molecules (CD33/CD56/CD117/CD138). cPC were also mostly quiescent with 
higher clonogenic potential than BMPC [31].
Mishima et al. investigated genomic characterization of MM patients using cPC and won-
dered if mutational profile of cPC is in concordance with mutational profile of PC from the 
BM. This study showed that both populations have similar mutations. Interestingly, 100% 
of clonal mutations found in PC from BM were also detected in cPC. Moreover, 99% of 
clonal mutations of cPC were also found in BMPC. Whole genome sequencing did not find 
any major differences between these two groups of MM cells, suggesting that the change 
in biological behavior of cPC could be based on the changes of expression of ncRNA mol-
ecules [32].




Cell-free DNA are short fragments of DNA not associated with a cell and found in PB and 
other body fluids, such as urine, saliva, breast milk and others [33–35]. The term cfDNA is 
a general term that includes circulating DNA of both healthy and tumor origin. As circulat-
ing tumor DNA (ctDNA) fragments represent only a fraction of total cfDNA, it is necessary 
to distinguish the origin of fragments during analysis. Physiological levels of cfDNA in PB 
of healthy individuals are generally low (10–100 ng/ml). This changes, however, in case of 
various pathological events. Elevated levels of cfDNA were described in patients with inflam-
mation, trauma, sepsis, stroke or heart attack [36–38], but the highest levels of cfDNA were 
found in cancer patients, where they reached up to 1000 ng/ml [39, 40]. These findings suggest 
a correlation between levels of cfDNA and tumor burden. Nevertheless, cfDNA levels were 
not found to be cancer-specific. Stability of cfDNA is variable, ranging from 15 minutes to 
2.5 hours; therefore, the amount of cfDNA cannot be used as a diagnostic marker [41].
Cells can release cfDNA either actively, using exosomes [42], or passively by apoptosis and 
necrosis (Figure 1) [43, 44]. In 2016, however, a study by Bronkhorst et al. proposed that 
apoptosis and necrosis are not the source of cfDNA and that active secretion is primarily used 
for cfDNA release [45]. This proposal will require further investigation as it suggests a more 
active role of cfDNA in cell-to-cell communication. Since cfDNA is released directly from 
cells, circulating fragments contain the same genetic information as the original cell. In case of 
cancer cells, this allows detection of cancer-specific genetic and epigenetic aberrations, such 
as mutations, microsatellite alterations, changes in DNA methylation and others [41].
Figure 1. Schematic structure of release of circulating molecules and vesicles into bloodstream. miRNA – Micro RNA, 
lncRNA – Long non-coding RNA, cfDNA – Cell-free DNA and pre-miRNA – Precursor miRNA.
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In the field of MM research, only a small number of cfDNA studies have been published so far. 
The first pilot study was published by Sata et al. In 2015 [23] they compared ASO-PCR data from 
peripheral blood mononuclear cells (PBMC), BM mononuclear cells (BMMC), CD20 + CD38− 
B-cell population in BM and serum cfDNA. Even though the study was quite small and only 20 
patients (out of 30 enrolled) were quantifiable, it provided interesting results suggesting fur-
ther studies and validation are needed. A strong correlation between BMMC and PBMC was 
found, suggesting circulation of clonogenic PC in PB; PBMC also negatively correlated with 
treatment as ASO-PCR data from those cells always decreased after treatment. These results 
suggest a possibility to use PBMC instead of BMMC in monitoring of MRD in MM patients. 
In addition, DNA sequences found in cfDNA were identical to those found in BM cells in 
18/20 cases at diagnosis and 16/20 cases of follow-up samples, while levels of cfDNA remained 
mostly stable during the course of therapy. Based on these results, the authors assumed that 
detection of tumor V(D)J rearrangement in cfDNA can reflect presence and persistence of MM 
clones in patients. However, because of insufficient number of patients who reached complete 
remission (CR), the potential of cfDNA analysis for MRD monitoring remained unclear [46].
In 2017, three important studies on this topic were published [20, 47, 48]. The first by Kis et al. 
compared cfDNA analysis to BM analysis regarding molecular profiling of disease. This study 
screened 64 cfDNA samples from 53 MM patients for sequences of all protein-coding exons of 
KRAS, NRAS, BRAF, EGFR and PIK3CA genes. This method allowed for detection of tumor-
related fragment of cfDNA at significantly low allele frequencies (0.25%). In 48 cfDNA samples, 
matching BM data were available. The analysis detected 49/51 (96%) of somatic mutations in 
cfDNA that were also found in BM; importantly, four additional mutations not detected in 
BM samples were found in cfDNA (>98% specificity). There were two mutations missed by 
sequencing of cfDNA samples that were detected during validation by ddPCR in BM samples 
but not in cfDNA. These outcomes emphasize the potential of cfDNA analysis not only for com-
plex molecular profiling but also for detection of subclones not detected in BM aspirates [20].
The second important study, although once again lacking a larger patient cohort, was 
conducted by Oberle et al. and focused on detection of clonotypic V(D)J rearrangement in 
circulating MM cells and cfDNA. A cohort of 27 MM patients with various treatment regi-
mens based on bortezomib, lenalidomide and panobinostat was examined. NGS was used 
for identification and tracking of patient-specific V(D)J rearrangements. The identification of 
rearrangements was successful in only 23 out of 27 patients, and these patients underwent 
further screening of blood samples before and after initiation of therapy. Baseline screening 
detected patient-specific V(D)J rearrangement in 71% of cases in circulating MM cells and 
in 100% of cases in cfDNA. However, these values decreased in follow-up samples to 40% 
and 34%, respectively. The results also correlated with remission status of patients—91% of 
non-responders/progressors and 41% of responders to therapy had evidence of persistent 
MM in circulating cells or cfDNA. Interestingly, positivity in circulating MM cells and cfDNA 
associated with each other (P = 0.042) but disagreed in 30% of cases. This suggests that cir-
culating MM cells are not the only source of MM cfDNA and that cfDNA may reflect tumor 
burden more comprehensively. All these results indicate that V(D)J analysis from PB samples 
may be used for evaluation of treatment efficacy and possibly even for MRD prediction [48]. 
However, validation on a larger cohort is necessary.
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The last study was published by Mithraprabhu et al., and the subject of this study was muta-
tional characterization of MM. Paired DNA samples of BM PC and plasma derived cfDNA 
were analyzed for the presence of activating mutations of four oncogenes—KRAS, NRAS, 
BRAF and TP53 by NGS. In total, 48 MM patients (33 relapsed/refractory and 15 newly diag-
nosed) and 21 healthy donors (HD) enrolled in the study. Overall, 128 different mutations 
were detected in MM patients (cfDNA = 31, BM = 59 and both = 38), while none were found 
in HD. Interestingly, almost a quarter of all found mutations were detected only in cfDNA 
samples. These findings proved spatial heterogeneity of MM and showed that cfDNA mol-
ecules are derived from multiple tumor sites within a patient’s body. This was supported also 
by majority of cfDNA-specific mutations found in relapsed/refractory patients (30 mutations) 
in contrast to newly diagnosed patients (1 mutation) as they are more prone to have multiple 
focal lesions. Moreover, sequences of cfDNA were evaluated by ddPCR in seven patients 
throughout their treatment, and changes in fractional abundance were discovered, reflecting 
progression of disease. This proof-of-concept study confirmed the presence of mutations only 
in cfDNA and proved that genetic composition of MM is complex and evolves during pro-
gression of disease. In addition, it proposed that cfDNA analysis could be used as an adjunct 
to standard BM biopsy for disease monitoring to enable obtaining more complex results [47].
So far, not many cfDNA studies in MM have been conducted; however, the data are exciting 
and strongly suggest the future role of cfDNA in MRD monitoring.
4. Non-coding RNA molecules
Protein-coding genes comprise only about 1.5% of the genome. At the same time, it was 
shown that more than 90% is transcriptionally active [49]. Transcription of this so-called junk 
DNA leads to creation of thousands of RNA molecules that are not capable of coding pro-
teins. Surprisingly, it was shown that the more complex the organism, the higher number of 
non-coding RNA (ncRNA) molecules it contains [50]. These molecules have many different 
functions in the most important cell processes, such as differentiation, proliferation, apoptosis 
and many others. They are involved in tumorigenesis as well.
Based on their length, ncRNA are divided into two groups: short (sncRNA) and long (lncRNA). 
SncRNA are smaller than 200 nucleotides (nt), while lncRNA are longer than 200 nt. The first 
ncRNA molecules that were identified more than 50 years ago were ribosomal RNA (rRNA) 
and transfer RNA (tRNA) [4, 5, 51]. While there are many classes of ncRNA, the most studied 
and well known are microRNA (miRNA) and long non-coding RNA (lncRNA).
4.1. Definition and biogenesis of microRNA
MiRNA are short, non-coding, single-stranded RNA molecules about 21–23 nt long. They 
are involved in regulation of gene expression and influence various cell processes, such as 
proliferation, differentiation, apoptosis and tumorigenesis. MiRNA genes account for 1–2% 
of the human genome, and mature miRNA regulate around 50% of protein-coding genes [49].
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Based on the canonical model of miRNA biogenesis, miRNA genes are transcribed by RNA 
polymerase II or III into primary precursors, stem-loop structures (pri-miRNA) that contain 5′ 
end cap and polyA on the 3′ end. Pri-miRNA are cleaved in the nucleus by RNAse II enzyme 
Drosha and Pasha leading to pre-miRNA [52]. Pre-miRNA are exported into cytoplasm by 
transport protein exportin 5 [53]. In the cytoplasm, the pre-miRNA molecule is processed by 
the RISC complex that contains RNAse III Dicer and protein Argonaute 2 (Ago2). RISC complex 
cuts the molecule into 20–23 nt long double-stranded miRNA duplex with 2 nt overhang on 3′ 
ends [54]. One of the strands is the so-called guide strand and is complementary to the mRNA 
sequence. The other (‘passenger’ strand) is degraded. Which one of these strands is degraded 
is based on the stability of pairing on the 5′ end of the miRNA duplex [55]. Based on the level of 
miRNA/mRNA complementarity, the target mRNA is either silenced translationally in case of 
non-complete complementarity or degraded in case of 100% complementarity [56, 57].
MiRNA regulate a large spectrum of physiological and pathological processes including onco-
genesis; they can act as oncogenes or tumor suppressors. Several mechanisms of miRNA role 
in tumorigenesis have been described: increased expression levels, amplification, epigenetic 
silencing or loss of miRNA gene that regulates expression of a tumor suppressor gene [58]. On 
the other hand, deletion and epigenetic silencing of miRNA gene expression that silences onco-
gene expression have been described as well [59]. Moreover, mutations in target sequences of 
mRNA lead to failed translational repression or degradation of target mRNA [60].
In a pilot study of miRNA expression in malignant transformation of PC, increased expres-
sion of miR-181a/b, cluster miR-106b-25 (miR-93, miR-106b, miR 25) and miR-21 in MGUS and 
MM patients in comparison to healthy donors (HD) was found. Interestingly, MM patients 
showed increased expression of cluster miR-17-92a suggesting a possible role of this cluster 
in disease progression [61].
4.2. Circulating miRNA
Essentially, all human body fluids (PB, saliva, urine, breast milk, etc.) contain the so-called circu-
lating miRNA [62]. Circulating miRNA are quite stable and resistant to RNases as they are part 
of protein (Ago2) or lipoprotein (high-density lipoprotein (HDL)) complexes or they are bound 
inside exosomes—small transport vesicles [63]. It seems that circulating miRNA are involved 
in cell-to-cell communication as they are exported outside of cells based on biological stimuli. 
These molecules can also take part in cell processes, such as communication, proliferation, dif-
ferentiation and in case of tumors also metastases [64]. Specific profiles of circulating miRNA are 
diagnostic markers differentiating HD from patients, but they also correlate with progression 
and staging of the tumor [65, 66]. A major advantage of these molecules as potential biomarkers 
is their simple structure, easy access and measurability by standard laboratory techniques [64].
4.2.1. Circulating microRNA in monoclonal gammopathies
In MM, circulating miRNA were first described in 2012. In a study by Jones et al., PB serum 
samples of MGUS and MM patients were analyzed in comparison to HD. They found that 
miR-720, miR-1246 and miR-1308 could serve as potential markers of MG [67].
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The success of this study led to other studies, especially in MM. However, different approaches 
lead to varying results. The main differences were type of samples (serum or plasma of PB), 
design of experiments (patients vs. HD) and used methods and platforms.
Plasma of PB was reported to have lower levels of miR-92a in newly diagnosed MM patients in 
comparison to HD. Moreover, the level of miR-92a fluctuated based on progression of disease 
and treatment response, which would suggest a possible role of this miRNA as a predictive 
biomarker [68]. Another study showed increased expression of miR-148a, miR-181a, miR-20a, 
miR-221 and miR-88b in plasma of PB of MM patients in comparison with HD. Expression level 
of miR-20a and miR-148a was connected to shorter time to relapse of MM; this study suggested 
that circulating plasma miR-20a could be a marker of worse prognosis of MM [69]. On con-
trary, another study showed mostly decreased miRNA expression in MM patients compared 
to HD. MiR-483-5p and miR-20a were shown to have diagnostic and prognostic potential [70].
So far, most studies were performed using serum miRNA. Our own pilot study showed signifi-
cantly increased levels of miR-29a, miR-660 and miR-142-5p in MM patients in comparison with 
HD. We showed that circulating serum miR-29a could be a biomarker for MM patients [71]. In our 
follow-up study, we showed dysregulation of five serum miRNA, miR-744, miR-130a, let-7d, let-
7e and miR-34a in MGUS and MM patients in comparison with HD. Multivariate analysis showed 
that combination of miR-34a and let-7e distinguishes the patient cohorts with good sensitivity and 
specificity. Moreover, dynamics of serum miRNA with disease progression was shown [72].
In another study, increased expression of miR-181a/b, miR-221, miR-222 and miR-382 was 
found in relapsed MM patients and MM cell lines [51]. On contrary, lower expression of miR-
15a and miR-16 was described; these miRNA have been described in chronic lymphocytic 
leukemia and seem to be part of pathogenesis of this disease. The genes for these miRNA are 
coded in the 13q14 locus; this locus is often deleted also in MM [73]. MiR-15a and miR-16 sup-
port apoptosis and decrease proliferation of MM cells by AKT and MAP kinase signaling [51].
In a study by Rocci et al., higher levels of miR-25, miR-16 and miR-30a in MM patients cor-
related with longer overall survival (OS) [74]. Another study showed that miR-19a and miR-
4254 distinguish MM and HD. In addition, decreased level of serum miR-19a was positively 
correlated with international staging system (ISS) stage, presence of del(13q14) and gain 1q21 
and shorter progression-free survival (PFS) and OS. Surprisingly, these patients responded to 
bortezomib better [75].
Serum miRNA were also analyzed at CR after autologous stem cell transplantation (ASCT). MiR-
16, miR-17, miR-19b, miR-20a and miR-660 were decreased in diagnostic samples in comparison 
with CR samples [76]. Patients with lower levels of miR-19b and miR-331 had shorter PFS after 
ASCT. Level of miR-19b was significantly lower in samples obtained at relapsed than at CR.
The most common clinical manifestation of MM is osteolytic lesions. Increased levels of 
serum miR-214 and miR-135b were found in MM patients with osteolytic lesions, and their 
expression correlated with severity of the symptoms [77]. Moreover, increased level of miR-
214 associated with shorter PFS and OS.
Using NGS, miRNA (let-7b a miR-18a) from exosomes isolated from serum of MM patients 
significantly correlated with PFS and OS in univariate analysis and with ISS and cytogenetic 
abnormalities in multivariate analysis [78]. Moreover, it was shown that levels of exosomal 
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miR-16-5p, miR-15a-5p, miR-20a-5p and miR-17-5p were significantly decreased in MM 
patients resistant to bortezomib [79].
As for miRNA in other body fluids, our group performed analysis of circulating miRNA in 
urine of MM patients in comparison with HD. Unfortunately, we did not find any miRNA 
significantly dysregulated [13].
While a lot of work was done on circulating miRNA in MG, so far no clear biomarkers of the 
diseases have been identified. It is possible that MM as a heterogeneous disease will not have 
a single circulating miRNA as a biomarker. Further studies and standardization of sample 
processing, types of samples and analytical methods need to be performed.
In our opinion, miRNA have a large potential for diagnostics of monoclonal gammopathies. 
Most studies were done on diagnostics samples; however, the data are not consistent and 
more standardization and optimization is needed. The possibility of using miRNA as prog-
nostic or monitoring markers needs to be further validated.
4.3. Long non-coding RNA molecules
LncRNA are an abundant class of RNA between 200 nt and 100 kb long [80, 81]. To date, 
approximately 16,000 lncRNA have been identified in the human genome (http://www.gen-
codegenes.org/). On the other hand, the functional characterization of most of them has not 
been determined yet.
Genes encoding for lncRNA are present in many types of organisms, including animals [82], 
plants [83], yeast [84], prokaryotic organisms [85] and viruses [86]. LncRNA do not possess 
protein-coding capacity due to the absence of open reading frames (ORFs) or because of insuf-
ficient length of ORFs [87–90]. They can be classified according to their genomic localization 
into three major groups: long intergenic non-coding RNA (lincRNA), long intronic RNA and 
long non-coding RNA transcribed from specific genomic regions.
The expression of lncRNA genes is developmental and tissue-specific, and they have been associ-
ated with a large spectrum of biological processes, for example, alternative splicing, modula-
tion of protein activity, alternation of protein localization, epigenetic regulation and generally 
regulation of gene expression. These molecules can be precursors of small RNA and even tools 
for miRNA silencing [91–96]. LncRNA play an important role both in physiological and patho-
logical processes. The deregulated expression levels of these molecules were identified in a large 
variety of tumor diseases: breast cancer [97], small-cell lung carcinoma [98] and also in MM [22]. 
It was shown that alterations in lncRNA can influence regulation of cancer progression [99]. 
Interestingly, lncRNA seem to have higher tissue specificity even in comparison with protein-
coding mRNA and miRNA. Thus, they are even more interesting as new specific biomarkers [88].
Function of lncRNA can also be derived from their localization within the cell. These mol-
ecules can be found in the nucleus and in the cytoplasm. LncRNA are preferably located in 
the cell nucleus, deriving their significant effect on the DNA sequence [88].
The classification of lncRNA can be based on their influence on the DNA sequence. From 
this perspective, there are two classes of lncRNA: cis-lncRNA (cis-acting lncRNA) and trans-
lncRNA (trans-acting lncRNA). Cis-IncRNA can positively or negatively regulate expression 
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of genes that are located in their genomic proximity [95]. On the other hand, trans-lncRNA 
regulate expression of distant genes [100]. Many lncRNA are transcribed by RNA polymerase 
II, just like protein-coding genes. If lncRNA are involved in the regulation of RNA polymerase 
II, they are transcribed by RNA polymerase III [87, 101–103]. High degree of evolutionary 
conservation, tissue-specific expression and stability of lncRNA point to significant functional 
role of these molecules [104].
Dysregulation of lncRNA expression was observed in various human diseases, including 
cancer. LncRNA may be either oncogenes or tumor suppressors in development as well as 
progression of tumors [105, 106]. Changes of expression levels of several lncRNA have been 
reported in several malignancies; other lncRNA seem to be specific for a single tumor, sug-
gesting that these molecules may be good biomarkers for tumor diagnostics as well as prog-
nosis and prediction [107].
Moreover, it was shown that lncRNA are involved in regulation of hematopoiesis, including 
proliferation, differentiation and apoptosis of hematopoietic stem cells as well as progeni-
tors and precursors of mature blood cells [108, 109]. Dysregulated expression of lncRNA was 
reported in lymphomas, leukemias and MM. It seems possible that expression profile of these 
lncRNA could have a potential clinical significance in diagnostics and prognostics of hema-
tologic malignancies.
Current information about the role of lncRNA in pathogenesis of MM is very limited. So far, 
MALAT1 has been described as a marker of early progression [110]. Expression level of this 
lncRNA was increased in BM cells of newly diagnosed MM patients and changed during progres-
sion of the disease. Patients with lower levels of MALAT1 had a higher risk of early progression.
Handa et al. showed higher expression level of MALAT1 in MM patients in comparison 
to MGUS and HD [111]. These results are in correlation with another study of Ronchetti 
et al. who showed dysregulation of 31 lncRNA, including MALAT1, in MM patients [112]. 
Moreover, this lncRNA may be important in MM pathogenesis through activation of TGF-β, 
a factor important for osteolytic lesion formation [113].
An earlier study showed decreased expression of MEG3 in MM patients [114]. Decreased 
expression or loss of this lncRNA seems to be important in various types of human tumors 
[115]. In a study by Benetatos et al., MEG3 was reported to be lost in more than half of MM 
patients, and it seemed to have a prognostic significance for MM [116].
Our own study showed that UCA1 might be a marker of MM when HD, MGUS and MM 
plasma cells were compared (with sensitivity of 85.0% and specificity of 94.7%). UCA1 levels 
seemed to correlate with albumin and monoclonal immunoglobulin serum levels, cytogenetic 
aberrations, and survival of MM patients.
4.3.1. Circulating lncRNA
Similar to circulating miRNA, even lncRNA may be detected in body fluids suggesting their 
possible role as biomarkers for diagnosis, prognosis and prediction. They were found in PB 
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and urine, but they can also be found within exosomes where they are protected against 
RNases [117].
Most studies of circulating lncRNA published so far were studies of solid tumors. In prostate 
cancer, PCA3 specificity was so high that a new test from urine has been approved for usage 
in Europe; it can be used together with currently used PSA test (prostate-specific antigen) 
[118–121].
In urinary bladder cancer, increased level of UCA1 was detected not only in the tumor tissue 
but also in PB and urine of patients [79, 122]. It was shown that based on UCA1 expression, 
urinary bladder cancer may be distinguished from other urinary bladder diseases with high 
specificity [28].
Unfortunately, only very few studies were published about circulating lncRNA in MM. In 
a study of Isin et al. [123], five candidate lncRNA (TUG1, MALAT1, HOTAIR, GAS5, 
lincRNA-p21) were analyzed in plasma of PB of MM patients in comparison with CLL 
patients [103]. Plasma of PB of CLL patients contained significantly deregulated levels of 
lincRNA-p21. On the other hand, MM plasma contained deregulated levels of the other 
four lncRNA. When compared to HD, MM patients contained only TUG1 deregulated 
levels. There was a correlation of circulating lncRNA and clinical subgroups of MM, sug-
gesting that TU1 could be a part of MM progression. Another study reported significantly 
higher levels of PCAT-1 in MM patients in comparison with HD. Its potential as a bio-
marker was proven by ROC analysis that showed sensitivity of 71.7% and specificity of 
93.8%. A possible correlation with MM pathogenesis was suggested by a correlation with 
β2 microglobulin [123].
While lncRNA molecules are generally described as being more tissue-specific than miRNA, 
not enough data have been published on circulating lncRNA in MM. Further studies that are 
more comprehensive are needed to verify their claim as the more specific marker.
5. Conclusion
While not many studies have been published dealing with liquid biopsies of circulating mol-
ecules in multiple myeloma, they show a great promise. Liquid biopsies could be used as 
an adjunct to standard BM biopsy for disease monitoring to enable obtaining more complex 
results and easier follow-up of patients. While there are many candidate molecules that have 
been described in this review (cfDNA, miRNA and lncRNA), more studies are needed to 
validate these findings.
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